Wednesday, July 16, 2025

Interactive Brokers Unveils Investment Themes Tool to Turn Market Trends into Smarter Trades

  GREENWICH, Conn. - Wednesday, 16. July 2025 AETOSWire 



New discovery feature helps investors quickly explore market trends, compare companies, and find opportunities


(BUSINESS WIRE)--Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced the release of Investment Themes, an intuitive discovery tool powered by Reflexivity that investors can use to move from market trends to actionable trade ideas more quickly and confidently. Available across IBKR’s powerful trading platforms, Investment Themes simplifies the research process by connecting companies, products, competitors, and regions across the entire S&P 1500 universe.


The underlying thematic intelligence was developed by Reflexivity, leveraging its proprietary knowledge graph to map the real-world relationships between companies and their business drivers.


Investment Themes turns complex market data into clear, interactive insights. Investors can start with a topic like “Generative AI” or “Nuclear Energy” and instantly view the public companies tied to that theme, without needing a ticker symbol or prior research. Investment Themes helps users uncover patterns, explore relationships, and make informed decisions in less time.


“Investment Themes will help our clients turn raw relationship data into a narrative that they can trade on,” said Steve Sanders, EVP of Marketing and Product Development at Interactive Brokers. “It’s about helping investors turn curiosity into conviction more efficiently.”


“IBKR has always been on the cutting edge of technology, offering its clients state-of-the-art trading and research infrastructure,” said Jan Szilagyi, the Co-founder and CEO of Reflexivity. “This initiative demonstrates how AI can deliver value to pioneering institutions that care deeply about their client experience.”


Investment Themes transforms complex market relationships into actionable intelligence and allows investors to:


Start with a trend and discover investable companies: By typing in a theme, users can quickly see companies that are directly connected to that idea, eliminating the need for complex filters or prior watchlists.

Leverage a dynamic universe: Investment Themes consists of ~500 real-world business areas and industry trends. The exposure of each company is measured based on a proprietary scoring system built by Reflexivity that assesses factors including revenue exposure, strategic importance, and capital expenditures associated with the theme.

Understand the competitive landscape: Each S&P 1500 company profile now includes an Investment Themes tab in Fundamentals Explorer. This view offers a map of that company’s products, direct competitors, and related industries, helping investors spot portfolio overlaps or discover complementary opportunities.

Explore global exposure and revenue footprints: Investment Themes includes capabilities to examine a company’s regional risk or growth potential by tracing where revenue is generated. Whether investors are looking to hedge exposure or identify global leaders, Investment Themes makes it easier to understand who is focused on which markets.

With Investment Themes, IBKR makes it easier for every investor to explore ideas, uncover relationships, and turn insight into action. In addition to Investment Themes, Interactive Brokers provides a comprehensive set of discovery tools, including global valuation comparisons, sentiment analysis, bond screening, and securities lending insights, designed to help investors uncover opportunities across markets, asset classes, and investment styles.


Investment Themes is available to IBKR clients worldwide at no additional cost. It is in beta on most platforms and will be generally available shortly. Clients using Trader Workstation can launch Investment Themes from the “New Window” menu or by opening one of the S&P 1500 stocks in Fundamentals Explorer and clicking on the Investment Theme tab. This tool is also available in equivalent locations in IBKR Mobile and IBKR Desktop.


For more information, visit:


US and countries served by IB LLC: Investment Themes

Canada: Investment Themes

United Kingdom: Investment Themes

Europe: Investment Themes

Hong Kong: Investment Themes

Singapore: Investment Themes

Australia: Investment Themes

India: Investment Themes

Japan: Investment Themes


The best-informed investors choose Interactive Brokers


About Interactive Brokers Group, Inc.:


Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities, foreign exchange, and forecast contracts around the clock on over 160 markets in numerous countries and currencies from a single unified platform to clients worldwide. We serve individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation have enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Interactive Brokers has consistently earned recognition as a top broker, garnering multiple awards and accolades from respected industry sources such as Barron's, Investopedia, Stockbrokers.com, and many others.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250716446710/en/



Permalink

https://www.aetoswire.com/en/news/1607202547949


Contacts

Contacts for Interactive Brokers Group, Inc. Media: Katherine Ewert, media@ibkr.com


 

Shapoorji Pallonji brings 158 years of luxury real estate expertise to the UAE


 Dubai, United Arab Emirates 

Receives the Building Completion Certificate from Dubai's Real Estate Regulatory Authority for its maiden venture – Imperial Avenue in Downtown Dubai


In a historic milestone, Shapoorji Pallonji, India’s 158-year-old real estate and construction giant, has officially completed its first-ever international and finest residential development, Imperial Avenue, in Downtown Dubai, marking a bold new chapter in the group’s global expansion journey.


Rising 45 storeys and offering panoramic views of Burj Khalifa and the Dubai Canal, Imperial Avenue boasts a 10,000 square foot grand entrance lobby and ultra-luxe amenities complete with infinity pools, a state-of-the-art fitness centre, and recreation areas coupled with sustainability features like solar panels and grey water treatment. With the Building Completion Certificate in hand from Dubai’s Real Estate Regulatory Authority (RERA), Shapoorji Pallonji is currently hosting homeowners for property inspection and handover.


Backed by AED 1.4 billion in investments, including funding from London-based Hayfin Capital and the UAE’s Commercial Bank International, the project is a bold move that reinforces Dubai’s appeal as a strategic market for international developers.


Announcing the completion, Mr. Cyrus Engineer - SP International Property Developers, said: “Imperial Avenue is more than a luxury tower; it’s a statement of intent. By combining our Indian engineering legacy with Dubai’s futuristic standards, we aren’t just handing over apartments but delivering a sustainable, tech-enabled lifestyle in the heart of Dubai's most prestigious address."


Aligning its expansion strategy with the global epicenter of luxury living, Dubai and the UAE were Shapoorji Pallonji’s obvious choice for mapping international boundaries. With unmatched demand from international buyers and Downtown Dubai’s appreciation potential consistently delivering at 8-12% ROI for luxury properties, the developer has confidently invested its legacy in Dubai’s future-ready real estate markets. “Dubai’s ambition mirrors our own—to create iconic, sustainable landmarks. Downtown’s dynamism offered the perfect stage to debut our international residential expertise." Mr. Cyrus Engineer added.


Attracting buyers from over 60 nationalities, the project offers a curated mix of 1- to 5-bedroom apartments, penthouses, and podium villas with private pools, designed to meet rising demand for larger, high-end homes with smart integrations and a hotel-calibre lifestyle. With sales expected to reach approximately AED 2 billion, this venture marks a significant milestone. As the group enters the international markets, this venture is a symbol of Shapoorji Pallonji’s transformation into a global luxury developer, cementing its position in Dubai’s real estate renaissance.


About Shapoorji Pallonji and Company Pvt Ltd


Established in 1865 in India, SP is a globally diversified institution, with a leading presence in the sectors of Engineering & Construction, Infrastructure, Real Estate, Water, Energy, and Financial Services. It has a strong employee base of over 70,000 people, delivering end-to-end solutions across 70 nations. SP’s focus is on building megastructures, developing multifaceted iconic landmarks, driving innovative technologies in water management, renewable energy, oil & gas, and power, all with good governance and sustainable development, to engineer a better planet.


About Imperial Avenue, Downtown Dubai


Imperial Avenue – SP’s finest residential development to date is an exclusive collection of luxury homes in Downtown Dubai overlooking Burj Khalifa and Dubai Canal. Complete with five levels of free-flowing podiums and state-of-the-art facilities, Imperial Avenue consists of 1-, 2-, 3-, and 4-bedroom apartments, 4- and 5-bedroom penthouses, 3-bedroom villas, and 4- and 5-bedroom villas with private pools at the podium level. Standing 45 storeys tall with 424 apartments and 5 levels of parking, Imperial Avenue emphasizes opulent living spaces offering high-quality living. With modular kitchens, designer bathrooms, and private decks, every apartment is unique.



Permalink

https://www.aetoswire.com/en/news/1507202547919


Contacts

Namita Thakkar


namita@matrixdubai.com

PUMA and Manchester City Announce Long-Term Extension to Successful Global Partnership

 HERZOGENAURACH, Germany - Tuesday, 15. July 2025


(BUSINESS WIRE) -- Sports company PUMA and Premier League football club Manchester City have signed a long-term extension of their partnership, which since the 2019/20 season has exceeded all expectations on and off the pitch.


The contract extension will allow PUMA and Manchester City to continue to innovate and create products that appeal to the club’s ever-growing global community of fans over the coming seasons.


“PUMA’s partnership with Manchester City has been a great success both on and off the pitch,” said PUMA Chief Executive Officer Arthur Hoeld. “Trophies, a perfect stage for our performance products and commercial success were exceptional.”


PUMA has celebrated many successes with the club during the partnership - most notably the Treble Winning 2022/23 season, four consecutive Premier League titles, and several domestic cup competition wins for the men’s first team and an FA Cup and League Cup victory for Manchester City Women.


During the partnership, Manchester City’s Elite Development Squad (EDS) has also secured four Premier League 2 titles and the Under-18s have won two FA Youth Cups and were named Premier League National Champions on three occasions.


Commercially, PUMA and Manchester City have set new club sales global records over the years and co-created iconic, best-selling kits such as the 2022/23 Colin Bell inspired home shirt worn during the treble-winning season.


“We joined forces with PUMA with the ambition to challenge ourselves and go beyond the expectations. We have achieved this and more over the last six seasons,” said Ferran Soriano, Chief Executive Officer of City Football Group. “PUMA have seamlessly integrated into our organisation, and we've enjoyed many historic moments together, engaging fans globally. Today’s renewal and extension solidifies our relationship and projects it to an even brighter future.”


PUMA and Manchester City have introduced industry-leading innovations both in terms of product and marketing campaigns over the past seasons. In 2022, they launched a kit in the metaverse for the first time with partner Roblox and more recently invited Man City fans to design a future kit by using AI technology.


PUMA’s subsidiary STICHD is the exclusive retail partner of Manchester City and helped expand the club’s retail footprint with the opening of City Stores in Manchester Arndale, within the ‘City Challenge’ in Yas Mall, Abu Dhabi and the four-month pop-up City Store at Rockefeller Centre, New York last summer. Manchester City’s online store ManCity.com is also operated by STICHD. As part of this new long-term partnership there is a commitment to continue the global expansion of the City Store network including a new flagship store as part of the ongoing development of the Etihad Campus.


Manchester City has also supported PUMA with sustainability initiatives such as its innovative RE:FIBRE recycling project. Since 2024, all Manchester City replica shirts are manufactured using RE:FIBRE materials that were recycled from factory off-cuts, faulty goods, and pre-loved clothing as the primary source of material.


PUMA are also partner of City Football Group clubs Melbourne City FC, Girona, Lommel, Mumbai City FC, Montevideo, Palermo, Bolivia and most recently Bahia and ESTAC.


PUMA


PUMA is one of the world’s leading sports brands, designing, developing, selling and marketing footwear, apparel and accessories. For more than 75 years, PUMA has relentlessly pushed sport and culture forward by creating fast products for the world’s fastest athletes. PUMA offers performance and sport-inspired lifestyle products in categories such as Football, Running and Training, Basketball, Golf, and Motorsports. It collaborates with renowned designers and brands to bring sport influences into street culture and fashion. The PUMA Group owns the brands PUMA, Cobra Golf and stichd. The company distributes its products in more than 120 countries, employs about 20,000 people worldwide, and is headquartered in Herzogenaurach/Germany.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250715122401/en/



Permalink

https://www.aetoswire.com/en/news/1507202547905


Contacts

Media Contact: Robert-Jan Bartunek – PUMA Corporate Communications – robert.bartunek@puma.com

KnowBe4 Delivers AI-Driven Email Security to Small and Medium Businesses to Tackle Outbound Email Risk

 


TAMPA BAY, Fla. -

Using advanced machine learning, neural networks and behavioral analytics, KnowBe4 Prevent mitigates outbound email data breaches


(BUSINESS WIRE)--KnowBe4, the world-renowned cybersecurity platform that comprehensively addresses human risk management, today announced the release of KnowBe4 Prevent across all market segments – an AI-driven email security product designed to enable organizations to manage the problem of outbound email risk. Following the release of Prevent Enterprise, Prevent is now available to suit the needs of small to medium-sized businesses.


In 2025, human error remains the leading cause of data breaches (according to Verizon, 60% of incidents involve the ‘human element’). The overwhelming volume of digital communications creates more opportunities for employees to expose sensitive information to the wrong recipients, attaching incorrect files, or inadvertently including confidential data. These breaches incur severe penalties, financial losses, and reputational damage, underscoring the critical need for prevention. However, traditional Data Loss Prevention (DLP) offerings rely solely on inflexible static rules and lack real visibility into what is being sent, to whom, and when.


To address this challenge, KnowBe4 introduces Prevent, an AI-native outbound email security product that alerts your employees in real time when they are about to send emails and attachments to the wrong person. Prevent proactively detects and stops the full spectrum of outbound email security threats, including:


Misdirected emails to incorrect recipients, including those as a result of autocomplete

Unauthorized sharing of sensitive information

Replies to suspicious emails and newly registered domains

Data exfiltration attempts by malicious insiders or compromised accounts

Misattached files, including hidden data within attachments (Prevent Enterprise)

Internal unauthorized disclosure and breach of information barriers (Prevent Enterprise)

Combined with detailed reporting and analytics, security teams are able to get a complete view of outbound security risk across the organization, behavioral analytics of users’ interactions with Prevent’s prompts and quantification of the prevented incidents to demonstrate efficacy and return on investment (ROI).


“Outbound email risk continues to be one of the most persistent and costly challenges an organization can face – one that requires smarter, more adaptive approaches to effectively address them,” said Greg Kras, chief product officer at KnowBe4. “KnowBe4 has a proven track record of effectively addressing Human Risk Management, so we are proud to expand that coverage to include outbound email risk. Prevent is the most intelligent and proactive outbound email security product among today's email data loss prevention methods. Unlike traditional products, it uses advanced machine learning and contextual understanding of user behavior to identify risky actions in real time and prevent a data breach before it occurs. This allows organizations to stop incidents at the source, empower employees to make safer decisions, and enable security teams to manage and reduce risk at scale.”


For more information on how KnowBe4 Prevent can help organizations mitigate outbound data loss over email, visit www.knowbe4.com/products/prevent. See how it helped KnowBe4 customer Publix Employee Federal Credit Union here.


About KnowBe4


KnowBe4 empowers workforces to make smarter security decisions every day. Trusted by over 70,000 organizations worldwide, KnowBe4 helps to strengthen security culture and manage human risk. KnowBe4 offers a comprehensive AI-driven ‘best-of-suite’ platform for Human Risk Management, creating an adaptive defense layer that fortifies user behavior against the latest cybersecurity threats. The HRM+ platform includes modules for awareness & compliance training, cloud email security, real-time coaching, crowdsourced anti-phishing, AI Defense Agents, and more. As the only global security platform of its kind, KnowBe4 utilizes personalized and relevant cybersecurity protection content, tools and techniques to mobilize workforces to transform from the largest attack surface to an organization’s biggest asset. More at https://knowbe4.com.


Follow KnowBe4 on LinkedIn and X.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250715426192/en/



Permalink

https://www.aetoswire.com/en/news/1507202547918


Contacts

Media Contact:

Amanda Tarantino

Sr. Manager of Public Relations

amandat@knowbe4.com

727-748-4221

7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations

 HONG KONG - Tuesday, 15. July 2025 AETOSWire 



(BUSINESS WIRE) -- MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap.


Priced at $0.35 per token, the entire allocation was claimed almost instantly. This exceptional level of interest marks one of the most successful offerings in the digital asset space this year, highlighting intense demand for asset-backed products with real-world utility.


Following thousands of additional requests, MultiBank Group will open a second and final $MBG Token Pre-Sale on Friday 18th of July, ahead of the official Token Generation Event (TGE) on July 22. This last round will feature 3 million tokens at the exclusive price of $0.35, giving early participants one last chance to join before trading begins. The final $MBG Token Pre-Sale will be available through multibank.io and Uniswap.


Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting the experience, resources, and global reach that underpin everything we do at MultiBank Group. The market has spoken, and it has spoken with speed and conviction.”


Supported by $29 billion in assets across the group’s 4 Pillars and powered by over $35 billion in daily turnover, $MBG token is engineered for substance showcasing the proven track record and compliance of one of the industry’s most trusted names.


MultiBank Group’s ecosystem is designed for resilience and growth, anchored by four pillars:


MultiBank TradFi: A global CFD leader, generating $362 million in revenue in 2024.


MEX Exchange: A $23.7 billion institutional-grade marketplace launching later this year.


MultiBank.io RWA: Bringing $3 billion in tokenized ultra-luxury real estate to market.


MultiBank.io: Expanding into crypto derivatives alongside the sale.


Together, these platforms will drive a $440 million buyback and burn initiative, reinforcing demand, ensuring a deflationary supply, and sustaining value growth for $MBG holders.


For more information, visit token.multibankgroup.com and follow us on Telegram for real-time updates.


ABOUT MULTIBANK GROUP


MultiBank Group, established in California, USA in 2005, is a global leader in financial derivatives. With over 2 million clients in 100+ countries and a daily trading volume exceeding $35 billion, it offers a broad range of brokerage and asset management services. Renowned for innovative trading solutions, robust regulatory compliance, and exceptional customer service, the Group is regulated by 17+ top-tier financial authorities across five continents. Its award-winning platforms provide up to 500:1 leverage across Forex, Metals, Shares, Commodities, Indices, and Cryptocurrencies. MultiBank Group has received over 80 international awards for trading excellence and regulatory compliance. For more information, visit MultiBank Group’s website.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250715055611/en/



Permalink

https://www.aetoswire.com/en/news/1507202547928


Contacts

mohammad.shakfeh@multibankfx.com

00971585754191

Tuesday, July 15, 2025

SES Receives All Required Regulatory Approvals to Complete Intelsat Acquisition

LUXEMBOURG - Tuesday, 15. July 2025


(BUSINESS WIRE)--SES received the final regulatory approvals for the SES-Intelsat transaction, including the US Federal Communications Commission.


On 30 April 2024, SES and Intelsat announced an agreement for SES to acquire Intelsat for a cash consideration of $3.1 billion (€2.8 billion). The transaction was subject to receipt of relevant regulatory clearances and other relevant requirements which all have now been obtained.


As a result, SES plans to close the transaction on or about Thursday, 17 July 2025. Once closing has occurred, a press release will be published to confirm that the transaction has successfully closed.


Follow us on:


Twitter | Facebook | YouTube | LinkedIn | Instagram


Read our Blogs >

Visit the Media Gallery >


About SES


SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and operates a geosynchronous earth orbit (GEO) fleet and medium earth orbit (MEO) constellation of satellites, offering a combination of global coverage and high-performance services. By using its intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners around the world. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.


Forward-Looking Statements


This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933. Generally, the word “will” and similar expressions or their negative, may, but are not necessary to, identify forward-looking statements.


Such forward-looking statements, including those regarding the timing and consummation of the transaction described herein, involve risks and uncertainties. SES’s and Intelsat’s experience and results may differ materially from the experience and results anticipated in such statements. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions including, but not limited to, the following factors: the risk that the conditions to the closing of the transaction are not satisfied; litigation relating to the transaction; uncertainties as to the timing of the consummation of the transaction and the ability of each party to consummate the transaction; risks that the proposed transaction disrupts the current plans or operations of SES or Intelsat; the ability of SES and Intelsat to retain and hire key personnel; competitive responses to the proposed transaction; unexpected costs, charges or expenses resulting from the transaction; potential adverse reactions or changes to relationships with customers, suppliers, distributors and other business partners resulting from the announcement or completion of the transaction; the combined company’s ability to achieve the synergies expected from the transaction, as well as delays, challenges and expenses associated with integrating the combined company’s existing businesses; the impact of overall industry and general economic conditions, including inflation, interest rates and related monetary policy by governments in response to inflation; changes in tariffs, import and export control laws and regulations, as well as related guidance; geopolitical events, and regulatory, economic and other risks associated therewith; and continued uncertainty around the macroeconomy. Other factors that might cause such a difference include those discussed in the prospectus on Form F-4 filed in connection with the proposed transaction. The forward-looking statements included in this communication are made only as of the date hereof and, except as required by federal securities laws and rules and regulations of the SEC, SES and Intelsat undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Additional Information and Where to Find It


In connection with the proposed strategic business combination between SES and Intelsat, SES filed with the SEC a registration statement on Form F-4 (SEC File No. 333-286828) that included a prospectus of SES. The registration statement was declared effective by the SEC on May 14, 2025, and the prospectus was mailed or otherwise disseminated to the shareholders of SES and Intelsat. SES also has filed and plans to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SHAREHOLDERS ARE URGED TO READ THE PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and shareholders can obtain free copies of the prospectus and other documents filed with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC will be available free of charge on SES’s website at www.ses.com or by contacting SES’s Investor Relations Department by email at ir@ses.com. Copies of the documents filed with the SEC by Intelsat will be available free of charge on Intelsat’s website at www.intelsat.com or by contacting Intelsat’s Investor Relations Department by email at investor.relations@intelsat.com.


No Offer or Solicitation


This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250714061669/en/



Permalink

https://www.aetoswire.com/en/news/1507202547895


Contacts

For further information please contact:


Suzanne Ong

Communications

Tel. +352 710 725 500

suzanne.ong@ses.com


Christian Kern

Investor Relations

Tel: +352 710 725 7787

christian.kern@ses.com

Deltatre Announces Acquisition of Endeavor Streaming to Create Digital and Streaming Platform Leader

 LONDON & NEW YORK - Tuesday, 15. July 2025 AETOSWire Print 



(BUSINESS WIRE) -- Deltatre, a leading international provider of streaming, digital, data, and graphics solutions for the sports, media, and entertainment industries, today announced it has entered into a definitive agreement to acquire Endeavor Streaming from Endeavor Group Holdings, Inc.


In bringing together these complementary and proven digital and OTT providers, Deltatre is joining its advanced product suite – D3 VOLT, FORGE, AXIS, and DIVA, which delivers multi-functional digital experiences with integrated video – with Endeavor Streaming’s pure-play OTT product, VESPER. They will also unite their digital strategy, consulting, and direct-to-consumer growth marketing services.


The combined business will be best equipped to deliver for sports, media, and entertainment clients through a compelling and comprehensive range of digital experiences – all within a centralized partnership with Deltatre – moving away from the complexity of tactical, multi-vendor service provider deployments.


The joint portfolio of clients includes many of the world’s most prominent sports and media properties – including the NFL, UFC, Sky, Rogers, NBA, WWE, MLB, BritBox, Bell Media, LIV Golf, ICC, World Rugby, and UEFA – reflecting decades of experience delivering digital and OTT services with proven quality, reliability, and performance at scale.


“Together, we are extremely well-positioned to lead at every level of the industry – and this investment underscores our commitment to broadening the value we bring to existing and future clients. Endeavor Streaming is a highly respected player in our industry and its offerings are a natural complement to our existing products and services,” said Andrea Marini, CEO of Deltatre. “I strongly believe this move positions Deltatre as a leader in delivering high-quality, fully integrated digital and OTT deployments.”


“Endeavor Streaming has established itself as a trusted partner to the world’s largest sports and media companies, as they transition their businesses from linear-driven experiences into a direct-to-consumer driven future,” said Fred Santarpia, President of Endeavor Streaming. “With Deltatre, we look forward to delivering even greater opportunities to create value for our partners in growing audiences and revenue.”


Deltatre and Endeavor Streaming have also focused heavily on the productization of their platforms and services – enabling repeatable, cost-effective, and rapid deployment – coupled with a large engineering function for customized launches. Together, the companies will be positioned to continue serving the largest global platforms as well as smaller properties and regional players.


The acquisition further strengthens Deltatre’s global footprint with extended operational support across the U.S., Europe, the Middle East, and Asia.


The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions.


Weil, Gotshal & Manges LLP is serving as legal advisor to Deltatre, and New Deal Advisors SpA is acting as its financial advisor. Latham & Watkins LLP is serving as legal advisor to Endeavor Group Holdings, Inc., and The Raine Group is acting as its financial advisor.


About Deltatre


Deltatre is the tech company behind the media and sporting moments that matter. Over nearly four decades, it has built the trust of many of the world’s biggest broadcasters, telcos, sports teams, leagues, federations, and governing bodies. Driven to create the digital experiences of tomorrow, it continues to redefine how the value of live and on-demand sports, film, TV, and news content is maximized. It specializes in video streaming, websites, apps, sports data, graphics, and officiating systems, and clients include the BBC, Rogers, Bell Media, Danish Broadcasting Corporation, Mediacorp, beIN, CPL, UEFA, ATP, NFL, DFL, NHL, MLS, MLB, and World Athletics.

www.deltatre.com


About Endeavor Streaming


Endeavor Streaming is a global leader in premium video distribution and monetization for live and on-demand content across sports, entertainment, media and lifestyle. Through its complete end-to-end streaming platform and unique service offerings inclusive of advisory and consultancy, growth marketing, custom front-end development and more, Endeavor Streaming helps content creators, brands and rights holders transform, grow and scale their direct-to-consumer businesses. Endeavor Streaming is a trusted partner for leading global brands, delivering tens-of-thousands of major tentpole events annually including UFC fight cards and powering streaming services including University of Texas’ LHN, WNBA League Pass, UFC FIGHT PASS, NWSL, and more.

www.endeavorstreaming.com


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250715833650/en/



Permalink

https://www.aetoswire.com/en/news/1507202547926


Contacts

James McFarland

press@deltatre.com

Loomis Sayles Celebrates 15 Years of Growth Equity Strategies Team Under Leadership of Aziz V. Hamzaogullari

BOSTON - Tuesday, 15. July 2025


(BUSINESS WIRE)--Loomis, Sayles & Company:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714614048/en/


Loomis, Sayles & Company proudly celebrates the 15-year anniversary of a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors.


GES is a cohesive team with nearly 19 years of alpha generation and a long-term, private equity approach to investing.

Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to nearly $91 billion as of 31 May 2025.

Aziz brought a differentiated approach to equity investing when he joined Loomis Sayles in 2010. A proprietary seven-step research framework supports the GES Team’s long-term, private equity approach to investing. The Team seeks to invest in those few high-quality businesses with sustainable competitive advantages and profitable growth only when they trade at a discount to the GES estimate of intrinsic value.


Underpinned by this singular investment philosophy, the GES Team expanded its platform from US-focused Large Cap Growth and All Cap Growth strategies to also include Global Growth, International Growth long-only strategies as well as the Long/Short Growth Equity hedge fund strategy. These strategies also are available in vehicles available to US investors.


The GES Team believes a focus on the quality of a manager’s investment philosophy, process and decision-making is essential for assessing the probability of future success. The GES alpha thesis encapsulates a deeply held system of persistent beliefs, a rigorous, repeatable investment process and substantive proof points.


“Since joining Loomis Sayles in 2010, Aziz and the GES Team have consistently distinguished themselves through a relentless focus on striving to achieve superior risk-adjusted returns for investors. Backed by their differentiated approach, they have demonstrated skilled and disciplined decision-making as well as a strong performance track record of which we are very proud,” said Kevin Charleston, chief executive officer of Loomis Sayles.


“I would like to thank our investors for their trust. We will continue to be committed to our guiding principles of long-term investing based on our key differentiated insights,” said Aziz V. Hamzaogullari, CFA, founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies Team.


COMPOSITE PERFORMANCE AND RANKINGS (AS OF 31 MARCH 2025)


LARGE CAP GROWTH

Inception 7/1/2006

$84.1 BILLION AUM


Since inception in 2006, the Large Cap Growth composite has generated an annualized return of 14.19% (gross), 13.68% (net), outperforming the Russell 1000 Growth Index by 1.63% (gross), 1.12% (net), a gross return that ranks ahead of 98% of large cap growth peers.†


The Large Cap Growth composite seeks to produce long-term, excess returns vs. the Russell 1000® Growth Index on a risk-adjusted basis over a full market cycle (at least five years) through bottom-up stock selection.


Past performance is no guarantee of future results. Gross returns are net of trading costs. Net returns are gross returns less effective management fees. Indices are unmanaged and do not incur fees. It is not possible to invest directly in an index Please see trailing returns and other statistics as of the most recent quarter-end at the end of the document. †Ranking out of 159 observations (eVestment Alliance’s Large Cap Growth Universe.)


ALL CAP GROWTH

Inception 7/1/2006

$3.3 BILLION AUM


Since inception in 2006, the All Cap Growth composite has generated an annualized return of 14.14% (gross), 13.55% (net), outperforming the Russell 3000 Growth Index by 1.89% (gross), 1.30% (net), a gross return that ranks ahead of 95% of category peers**.


The All Cap Growth composite seeks to produce long-term, excess returns vs. the Russell 3000® Growth Index on a risk-adjusted basis over a full market cycle (at least five years) through bottom-up stock selection.


GLOBAL GROWTH

Inception 1/1/2016

$2.6 BILLION AUM


Since inception in 2016, the Global Growth composite has generated an annualized return of 13.55% (gross), 12.79% (net), outperforming the MSCI ACWI Gross Index by 2.85% (gross), 2.10% (net), a gross return that ranks ahead of 94% of global growth peers**.


The Global Growth composite seeks to produce long-term, excess returns vs. MSCI ACWI Gross Index on a risk-adjusted basis over a full market cycle (at least five years) through bottom-up stock selection.


INTERNATIONAL GROWTH

Inception 1/1/2020

$45.8 MILLION AUM


Since inception in 2020, the International Growth composite has generated an annualized return of 7.03% (gross), 6.18% (net), outperforming the MSCI ACWI ex-US Gross Index by 1.60% (gross), 0.75% (net), a gross return that ranks ahead of 62% of international growth peers**.


The International Growth composite seeks to produce long-term, excess returns vs. MSCI ACWI ex-US Gross Index on a risk-adjusted basis over a full market cycle (at least five years) through bottom-up stock selection.


LONG/SHORT GROWTH EQUITY

Inception 2/1/2012

$655.9 MILLION AUM


Since 2012, the Long/Short Growth Equity composite has generated an annualized return of 10.97% (gross), 9.33% (net), outperforming the S&P 500 50% Hedged Index by 3.89% (gross), 2.25% (net), the HFRI Equity Hedge (Total) Index* by 4.47% (gross), 2.83% (net) and the HFRI EH: Fundamental Growth Index by 5.61% (gross), 3.97 (net).


The Long/Short Growth Equity composite seeks to generate attractive long-term absolute positive returns regardless of market direction.


*The HFRI Equity Hedge (Total) Asset Weighted Composite Index is a global, asset-weighted index comprised of a single-manager funds that report to HFR Database. It is comprised of Equity Hedge fund peers that are not considered Equity Market Neutral. This index is being shown for informational and reference purposes only.


Source: Loomis Sayles, FTSE Russell, MSCI & HFR, as of 31 March 2025


The Portfolio Manager for the Growth Equity Strategies joined Loomis Sayles May 19, 2010, and his performance prior to that date was achieved at his prior firm.


Gross returns are net of trading costs. Net returns are gross returns less effective management fees. Returns may increase or decrease as a result of currency fluctuations. Indices are unmanaged and do not incur fees. It is not possible to invest directly in an index.


Any investment that has the possibility for profits also has the possibility of losses, including the loss of principal.


Please request a current presentation book for each strategy for more information regarding risks and GIPS reports.


Please see trailing returns and other statistics as of the most recent quarter-end at the end of the document. **Rankings out of 37 observations (eVestment Alliance’s All Cap Growth Universe.) Ranking out of 821 observations. (eVestment Alliance’s Global Large Cap and Global All Cap Equity Universes). Ranking out of 248 observations (eVestment Alliance’s ACWI ex-US Large Cap and ACWI ex-US All Cap Equity.)


Past performance is no guarantee of future results.


KEY INVESTMENT RISKS FOR THE LARGE CAP GROWTH, ALL CAP GROWTH, GLOBAL GROWTH, AND INTERNATIONAL GROWTH STRATEGIES

Equity Risk

The risk that the value of stock may decline for issuer-related or other reasons.

Market Risk

The risk that the market value of a security may move up or down, sometimes rapidly and unpredictably, based upon a change in market or economic conditions.

Non-US Securities Risk

The risk that the value of non-US investments will fall as a result of political, social, economic or currency factors or other issues relating to non-US investing generally. Among other things, nationalization, expropriation or confiscatory taxation, currency blockage, political changes or diplomatic developments can negatively impact the value of investments. Non-US securities markets may be relatively small or underdeveloped, and non-US companies may not be subject to the same degree of regulation or reporting requirements as comparable US companies. This risk is heightened for underdeveloped or emerging markets, which may be more likely to experience political or economic stability than larger, more established countries. Settlement issues may occur.

Smaller or Mid-Sized Companies Risk

The risk that the equity securities of these companies may be subject to more abrupt price movements, limited markets and less liquidity than investments in larger, more established companies.

Liquidity Risk

The risk that the strategy may be unable to find a buyer for its investments when it seeks to sell them.

Non-Diversified Strategies

Non-diversified strategies tend to be more volatile than diversified strategies and the market as a whole.

Currency Risk

The risk that the value of investments will fall as a result of changes in exchange rates, particularly for global portfolios.

Derivatives Risk (for portfolios that utilize derivatives)

The risk that the value of the Strategy’s derivatives instruments will fall because of changes in the value of the underlying reference instrument, pricing difficulties or lack of correlation with the underlying investment.

Leverage Risk (for portfolios that utilize leverage)

The risk of increased loss in value or volatility due to the use of leverage or obtaining investment exposure greater than the value of an account.

Counterparty Risk

The risk that the counterparty to a swap or other derivatives contract will default on its obligations.

Models and Data Risk

The strategy may utilize quantitative model-based strategies. This is the risk that one or all of the quantitative or systematic models used may fail to identify profitable opportunities at any time. These models may incorrectly identify opportunities and these misidentified opportunities may lead to substantial losses. Models may be predictive in nature and may result in an incorrect assessment of future events. Data used in the construction of models may prove to be inaccurate or stale, which may result in investment losses.

General Risk

Any investment that has the possibility for profits also has the possibility of losses, including loss of principal.


KEY INVESTMENT RISKS – LONG/SHORT GROWTH EQUITY STRATEGY

Equity Risk

The risk that the value of the Strategy's investments in equity securities is subject to the risks of unpredictable declines in the value of individual securities and periods of below-average performance in individual securities or in the equity market as a whole.

Short Sale Risk

The risk of losing an amount greater than the amount initially invested. Short selling is limited only by the maximum attainable price of the security less the price at which it was sold and is considered a form of leverage.

Non-Us Securities Risk

The risk that the value of non-US investments will fall as a result of political, social, economic or currency factors or other issues relating to non-US investing generally. Among other things, nationalization, expropriation or confiscatory taxation, currency blockage, political changes or diplomatic developments can negatively impact the value of investments. This risk is heightened for underdeveloped or emerging markets, which may be more likely to experience political or economic stability than larger, more established countries. Settlement issues may occur.

Non-Diversification Risk

The risk that the portfolio’s value may decline due to movements in the price of one or a small number of investments.

Currency Risk

The risk that the value of investments will fall as a result of changes in exchange rates

Derivatives Risk

The risk that the value of the Strategy’s derivatives instruments will fall because of changes in the value of the underlying reference instrument, pricing difficulties or lack of correlation with the underlying investment.

Leverage Risk

The risk of increased loss in value or volatility due to the use of leverage or obtaining investment exposure greater than the value of an account.

Counterparty Risk

The risk that the counterparty to a derivatives contract will default on its obligations.


Strategies referenced herein are managed by Loomis, Sayles & Company, L.P.


CFA® and Chartered Financial Analyst® are registered trademarks owned by the CFA Institute.


Diversification does not ensure a profit or guarantee against a loss.


Indices are unmanaged and do not incur fees. It is not possible to invest directly in an index.


This material is not intended to provide tax, legal, insurance, or investment advice. Please seek appropriate professional expertise for your needs.


Source: MSCI. Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI’s express written consent.


Since 1926, Loomis, Sayles & Company has helped fulfill the investment needs of institutional and mutual fund clients worldwide. The firm’s performance-driven investors integrate deep proprietary research and risk analysis to make informed, judicious decisions. Teams of portfolio managers, strategists, research analysts and traders collaborate to assess market sectors and identify investment opportunities wherever they may lie, within traditional asset classes or among a range of alternative investments. Loomis Sayles has the resources, foresight and the flexibility to look far and wide for value in broad and narrow markets in its commitment to deliver attractive, risk-adjusted returns for clients. This rich tradition has earned Loomis Sayles the trust and respect of clients worldwide, for whom it manages $390.1 billion* in assets (as of 31 March 2025).


*Includes the assets of both Loomis, Sayles & Co., LP, and Loomis Sayles Trust Company, LLC. ($33.9 billion for the Loomis Sayles Trust Company). Loomis Sayles Trust Company is a wholly owned subsidiary of Loomis, Sayles & Company, L.P.


Loomis Sayles Investments Limited ("LSIL") is a subsidiary of Loomis, Sayles & Company L.P., and it is authorised and regulated by the Financial Conduct Authority.


8124886.1.1


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250714614048/en/



Permalink

https://www.aetoswire.com/en/news/1507202547893


Contacts

Loomis Sayles Media Relations

+1 (617) 960-4447

Mary Kay Unveils 2025 Sustainability Report, Underscoring Key Milestones Across Social, Economic, and Environmental Spheres

  (BUSINESS WIRE)--Mary Kay Inc., a global advocate for sustainability and women’s empowerment, today announced the release of its 2025 Sustainability Report, a comprehensive overview of the company’s 2030 commitments and 2024 milestone achievements for creating positive impact around the world.

The annual report highlights Mary Kay’s decades-long dedication to social, economic, and environmental sustainability – core pillars central to its business strategy and its purpose-driven legacy rooted in the company’s mission of “enriching women’s lives” around the world.

“For over 60 years, our company has championed a business model and key initiatives that empower women, help protect the planet, and model resilient communities,” said Ryan Rogers, Chief Executive Officer of Mary Kay. “This year’s report reaffirms our goals and commitments, while celebrating the measurable and meaningful impact we are creating worldwide.”

From product stewardship and biodiversity preservation to advancing women’s equality and economic inclusion, and accelerating digitalization efforts to unleash entrepreneurship, Mary Kay continues to integrate sustainability into every facet of its business. Below are key 2024 highlights:


Environmental:

• Responsible Packaging: Reaffirmed our commitments to reducing plastic intensity, increase post-consumer recycled content (PCR), and increase recycle-ready/recyclable packaging1. For example, the bottle of Mary Kay TimeWise® Targeted-Action® Toning Lotion contains 94% PCR content.

• Sustainable Sourcing: 93% of Roundtable on Sustainable Palm Oil (RSPO) certified Palm Oil is used by our suppliers as of 2024 and 80% of our Shea use was sourced from the Global Shea Alliance (GSA) member suppliers.

• Water Management: 100% of the water used at our Richard R. Rogers (R3) global R&D and Manufacturing facility in Texas is treated and recycled back into the local watershed.

• Impact Partnerships: Celebrated 37-year partnership with The Nature Conservancy (TNC) representing 100 conservation projects supported and 16-year partnership with the Arbor Day Foundation (ADF) to preserve ecosystems in Texas and around the world through 34 projects.


Social:

• Pink Changing Lives®: $230 million USD donated in monetary and in-kind donations by Mary Kay Inc. and its four Company-sponsored foundations globally since 19962.

• Women’s Empowerment: 600K+ women positively impacted globally through meaningful programs at the global, regional, and local levels as of 2024.

• Future of STEM: 37 grants awarded to young women from 16 countries pursuing STEM careers and 8 grants awarded to female students through the “Madam C.J. Walker Scholarships” with The Society of Cosmetic Chemists (SCC) sponsored by Mary Kay as of 2024.

• Impact Partnerships: Mary Kay served as a special award organization at the International Science and Engineering Fair (ISEF) in 2024.


Economic:

• Women Powered: 63% of the global workforce at Mary Kay are female and 57% of leadership positions are held by women in our top 10 markets. 60% of our Executive team is female3.

• Global Footprint: Mary Kay expanded into Kyrgyzstan.

• Digitalization: Reimagined the digital selling experience through embracing digital opportunities while maintaining the hallmark of personalized service and attention our Independent Beauty Consultants (IBCs) are known for. In 2024, Mary Kay launched the “Phygital” campaign in Mexico and Brazil with Colombia to follow in 2025.

• Advocacy: Engaged in 100+ trade associations globally on a range of policy issues from direct selling and entrepreneurship to personal care and supply chain and logistics. In Brazil, Mary Kay contributed to the G20 Employment & Education Task Force (B20) Policy Paper.

IN 2024 AND 2025, MARY KAY EARNED SIGNIFICANT RECOGNITIONS:


• Named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World4 by Euromonitor International for three consecutive years, in 2023, 2024, and 2025.

• Ranked #9 on Forbes’s Best Brands for Social Impact 2025 out of 3,900 brands. Mary Kay is the only beauty brand in the Top 10 and the only direct selling company on the list.

• Ranked #11 in the Women’s Wear Daily Beauty Inc.’s 2024 Top 100 Beauty Companies released in 2025.

• Five Stars rating on Newsweek 2025 America’s Greatest Workplaces for Women.

• Honored with a “Leadership in Conservation and Sustainability Award” by Texan By Nature (TxN) in 2023 and again in 2024.

• Received a 2024 “Top Supply Chain Award” by The Supply & Demand Chain Executive for priority work on a shipment visibility solution in partnership with Tive, a leading provider.

Mary Kay’s 2025 Sustainability Report is aligned with the United Nations Sustainable Development Goals (SDGs) and serves as a benchmark for stakeholders and partners seeking to drive collective impact.


To view the full report, visit here.


About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X


1 Recyclable only where facilities exist.

2 While the Company has provided philanthropic support to charitable causes for many decades, official documentation began in 1996 with the founding of the Mary Kay Ash Foundation® (U.S.).

3 Women Representation and Leadership at Mary Kay (May 2025).

4 “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data”


 


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250715989652/en/



Permalink

https://www.aetoswire.com/en/news/1507202547917


Contacts

Mary Kay Inc. Corporate Communications

marykay.com/newsroom

972.687.5332 or media@mkcorp.com

The 2025 Empire State Building Run-Up Returns Oct. 8

NEW YORK - Monday, 14. July 2025

Presented by NYU Langone Health and Powered by the Challenged Athletes Foundation

Lottery Opens July 14

(BUSINESS WIRE) -- The Empire State Building (ESB) announced today general lottery registration for the annual Empire State Building Run-Up (ESBRU) on Oct. 8, 2025, at 8 p.m. ESB also announced the ESBRU will be presented by NYU Langone Health and powered by the Challenged Athlete’s Foundation. General lottery registration will be open from July 14 through July 28, 2025.

In the 47th annual Run-Up, 225 runners will race up the iconic building’s 1,576 stairs to the world-famous Observatory. This year’s heats will include elite men and women, media, celebrities, New York City real estate brokers, building tenants, CAF athletes, members of the NYPD and FDNY, and the public, among others. On July 30, registered runners will be notified of their race status with participation costs of $175 per runner to be charged only upon acceptance from the lottery.

“We are delighted to welcome NYU Langone Health as our new sponsor and look forward to the arrival of athletes from across the globe for the world’s most famous tower race – the 47th Annual Empire State Building Run-Up,” said Tony Malkin, chairman and CEO of Empire State Realty Trust. “Runners will test their limits once again in this bucket list race to the top of Tripadvisor’s number one rated attraction in the world. We wish everyone good luck on the lottery.”

As presenting sponsor for the first time, NYU Langone Health is a fully integrated health system – with seven inpatient locations and more than 320 outpatient locations – that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation.

Challenged Athletes Foundation® (CAF) serves as the official charity partner of the ESBRU once again with a designated division for athletes with permanent physical disabilities and CAF supporters who raise funds to empower lives through sports. Runners can bypass the lottery and run with #TeamCAF with a guaranteed charity fundraising entry found online.

The 2025 ESBRU is produced by Super Race Systems.

More information about the Empire State Building Run-Up and the official lottery entry can be found online. Hi-res imagery and video from previous years can be downloaded here.

About the Empire State Building

The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience created an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. The Empire State Building Observatory Experience welcomes millions of visitors each year and was declared the #1 Attraction in the World – and #1 Attraction in the U.S. for the third consecutive year – in Tripadvisor’s Travelers’ Choice Awards: Best of the Best Things to Do, "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, and the #1 New York City attraction in Lonely Planet’s Ultimate Travel List.

Since 2011, the building has been fully powered by renewable wind electricity, and its many floors house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, X (formerly Twitter), Instagram, Weibo, YouTube, or TikTok.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250714493943/en/

Permalink
https://www.aetoswire.com/en/news/1407202547891

Contacts

Media Contact:
Empire State Realty Trust
Jamie Steinberg
jsteinberg@esrtreit.com

CSC Research Finds 40% of Enterprises Could Be at Risk of an Outage Due to SSL Expiration

 WILMINGTON, Del. - Monday, 14. July 2025 AETOSWire Print 


Domain control validation sunsets on July 15, 2025, putting many companies that rely on WHOIS email at risk for service disruption


 


(BUSINESS WIRE)--New research from CSC, an enterprise-class domain security provider and world leader in domain management, SSL management, brand protection, and anti-fraud solutions, indicates that as many as 40% of enterprises are at risk of unexpected service outages caused by out-of-date secure sockets layer (SSL) certificates. This threat stems from the reliance on WHOIS-based email addresses for domain control validation (DCV) that will be officially deprecated on July 15, 2025.


CSC analyzed over 100,000 global SSL certificate records and found that many organizations still use WHOIS email as their primary method for domain control validation, despite a 2024 vote by the CA/Browser Forum that mandates the deprecation of WHOIS-based validation due to its associated security vulnerabilities. After July 15, 2025, certificate authorities (CAs) will no longer accept WHOIS email for DCV, making alternative validation methods essential for uninterrupted operations.


Compounding the issue, 17% of companies surveyed by CSC are unaware of their current DCV method, suggesting a widespread lack of visibility and preparedness within IT and security teams. To mitigate the risk, companies should immediately audit their certificate management workflows and migrate to accepted DCV alternatives such as domain name system (DNS)-based validation or file-based web token methods.


“For years, WHOIS-based email was seen as the easiest, non-technical DCV method. Organizations that have not switched to alternative DCV methods risk serious consequences—from website outages to critical service failures. But the changes don’t stop there,” cautions CSC’s senior director of Technology, Security Products and Services, Mark Flegg. “Organizations also need to bear in mind further industry-wide shifts that will take place in the coming years. Any short-term fixes need to be aligned with this long-term trajectory where automation of certificates and DCV will become unavoidable. Organizations absolutely need to start their prep work now.”


From March 15, 2026, certificate life cycles will begin to shorten drastically—from 367 days to 200, then 100, and finally just 47 days by 2029. Correspondingly, DCV re-use periods will reduce from 367 to 200, 100, and then just 10 days by 2028. That means enterprises will be facing up to eight certificate renewals per year. With DCV at 10 days, it could mean revalidation every time a certificate needs to be re-issued.


To support enterprises through these transitions, CSC offers a comprehensive suite of digital certificate solutions that can tailor to any organization’s workflow. Its newly launched Domain Control Validation as a Service (DCVaaS)—available free of charge to its clients—streamlines the validation process, reducing certificate renewal times by up to 99% and alleviating the manual workload for IT teams.


To learn more about CSC’s DCVaaS and future-proof your digital certificate operations, request a consultation at cscdbs.com.


About CSC

CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands (Interbrand®) with focus areas in domain security and management, along with digital brand and fraud protection. As global companies make significant investments in their security posture, our DomainSecSM platform can help them understand cybersecurity oversights that exist and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss. CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—with a multidimensional view of various threats outside the firewall targeting specific domains. Fraud protection services that combat phishing in the early stages of attack round out our solutions. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250714470775/en/



Permalink

https://www.aetoswire.com/en/news/1407202547887


Contacts

For more information:

Joyson Cherian

W2 Communications

CSC@w2comm.com

CSC News Room


 

PCI Pharma Services Enters Next Phase of Growth With Strategic Investment from Bain Capital, Kohlberg, and Mubadala

 Investment Will Accelerate PCI’s Leading Position in CDMO, Delivering Life-Changing Therapies to Patients


Transaction Includes Continued Investment from Partners Group


(BUSINESS WIRE) -- PCI Pharma Services (“PCI” or the “Company”), a world-leading global contract development and manufacturing organization (CDMO) focused on innovative biotherapies, today announced that it received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and supported with significant reinvestment by Mubadala Investment Company (“Mubadala”). Partners Group will also continue to support the Company with a minority investment. Financial terms of the private transaction were not disclosed.


Headquartered in Philadelphia, Pennsylvania, PCI provides clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 450 successful product launches over the last five years and over 50 years in pharmaceutical services helping bring to life innovation to improve patient access and outcomes.


Kohlberg and Mubadala, both of which initially invested in PCI in 2020, and Bain Capital are partnering with PCI's management team, led by Chief Executive Officer Salim Haffar, to accelerate the Company’s growth trajectory, build upon its strong customer service experience, and further enable PCI clients to bring life-changing biopharmaceutical therapies to market. PCI will primarily focus on organic and inorganic growth initiatives, including expanding its suite of services and geographic reach. Leveraging global growth trends in biologics and specialized drug therapies, PCI’s future investments will include expansion of existing sterile fill-finish of injectables and high potent and specialized manufacturing capacity. The strategic investment will also enable the Company’s significant continued investment in the US, bolstering the nation’s critical pharmaceutical manufacturing and supply chain infrastructure.


Haffar said: “PCI has embarked on a purposeful journey to transform itself into a global CDMO by executing its successful growth strategy, providing industry-leading customer experience, and offering innovative and integrated supply chain solutions. I am grateful for the ongoing support of our existing investors and enthusiastically welcome Bain Capital and their deep, global healthcare and life science capabilities and expertise. Together we will grow PCI’s commercial, clinical trial services, and development and manufacturing businesses to meet the future demands of our biopharmaceutical customers.”


Matt Jennings, Chairman of PCI and an Operating Partner of Kohlberg, commented: “PCI’s world-class management team, combined with the support of experienced industry investors, has proven to be a very successful formula. We are delighted for Bain Capital to join PCI’s investor base, yielding an optimal combination aligned to support Salim and the management team to execute on their growth ambitions and value creation pathways.”


Devin O’Reilly, Partner at Bain Capital, said: “Anchored by an innovative, advanced platform that is consistently growing and setting new standards for the industry, PCI Pharma has built a well-deserved reputation as a differentiated partner to leading biopharma companies, ensuring critical therapies reach patients safely and efficiently. We look forward to working alongside Kohlberg to build on this strong foundation.”


Andrew Kaplan and Christina Dix, Partners at Bain Capital added: “We are excited to leverage our industry expertise and the collaboration of our global healthcare team to support Salim and PCI’s team of experienced industry leaders in the mission to drive innovation in advanced pharmaceutical services that improve patients’ lives and outcomes.”


Chris Anderson, Senior Partner of Kohlberg, added: “We are honored to have supported PCI’s transformation over the last five years into a leading global CDMO, positioned in the fastest growing markets and known for its proven experience meeting critical customer needs throughout the drug development and commercialization lifecycle. We are thrilled to be partnering with Bain Capital and are aligned to make new investments that will further elevate the Company’s capabilities and growth for many years to come.”


Mina Hamoodi, Head of Healthcare at Mubadala, said: “Our reinvestment in PCI reflects our deep conviction in the company’s mission, leadership, and long-term potential. At this important juncture, we are delighted to welcome Bain Capital, an industry-leading healthcare investor with deep expertise in growing pharma services businesses, as a partner. We look forward to partnering with Bain and Kohlberg, and working closely with PCI’s outstanding management team, as the company enters its next chapter of accelerated growth.”


Sujit John, Managing Director, Private Equity Health & Life Vertical, Partners Group, commented: "PCI's market position, reputation, and world-class capabilities strategically position the Company to be the partner of choice for customers. We look forward to supporting PCI and the new ownership group in driving the Company into its next phase of growth.”


Jefferies LLC acted as lead financial advisor to PCI and Moelis & Company LLC acted as co-advisor to PCI. Morgan Stanley & Co. LLC, and BofA Securities, Inc. acted as financial advisors to Bain Capital. Citi acted as a financial advisor to Mubadala.


Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as counsel to PCI and Kohlberg. Kirkland & Ellis LLP acted as counsel to Bain Capital. Skadden, Arps, Slate, Meagher & Flom LLP acted as counsel to Mubadala. Ropes & Gray LLP acted as counsel to Partners Group.


About PCI Pharma Services


PCI is a world-leading CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the healthcare services business. The company currently has 38 sites across seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain and Australia), and over 7,500 employees working to bring life-changing therapies to patients.


Leading technology and continued investment enable PCI Pharma Services to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and commercialization. Its clients utilize PCI as an extension of their business, and a collaborative partner with the shared goal of improving patients’ lives. For more information, visit pci.com.


About Kohlberg


Founded in 1987, Kohlberg is a leading U.S. middle market private equity firm based in Mount Kisco, New York. The firm invests in high-quality healthcare and services companies characterized by strong market positions, recurring revenue streams and resilient end markets, which it identifies through rigorous thematic research grounded in its White Paper Program. Leveraging its team of investment and operating professionals, Kohlberg works with management teams to accelerate growth, enhance operational excellence and create value. For more information, please visit www.kohlberg.com.


About Bain Capital


Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management. To learn more, visit www.baincapital.com. Follow @BainCapital on LinkedIn and X (Twitter).


About Mubadala Investment Company


Mubadala Investment Company is a sovereign investor managing a global portfolio, aimed at generating sustainable financial returns for the Government of Abu Dhabi.


Mubadala's $330 billion (AED 1.2 trillion) portfolio spans six continents with interests in multiple sectors and asset classes. Mubadala leverages its deep sectoral expertise and long-standing partnerships to drive sustainable growth and profit, while supporting the continued diversification and global integration of the economy of the United Arab Emirates.


Headquartered in Abu Dhabi, Mubadala has additional offices in New York, London, Rio de Janeiro, San Francisco and Beijing.


For more information about Mubadala Investment Company, please visit: www.mubadala.com.


About Partners Group


Partners Group is one of the largest firms in the global private markets industry, with around 1,800 professionals and over $150 billion in overall assets under management. The firm has investment programs and custom mandates spanning private equity, private credit, infrastructure, real estate, and royalties. With its heritage in Switzerland and its primary presence in the Americas in Colorado, Partners Group is built differently from the rest of the industry. The firm leverages its differentiated culture and its operationally oriented approach to identify attractive investment themes and to transform businesses and assets into market leaders. For more information, please visit www.partnersgroup.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250714606219/en/



Permalink

https://www.aetoswire.com/en/news/1407202547885


Contacts

For PCI

Christopher Dale

Turchette Agency

973-227-8080 ext. 116

cdale@turchette.com


For Kohlberg

Amanda Shpiner/Iain Hughes

Gasthalter & Co.

212-257-4170

media@kohlberg.com


For Bain Capital

Charlyn Lusk/Scott Lessne

Stanton

646-502-3549/646-502-3569

clusk@stantonprm.com/slessne@stantonprm.com


For Mubadala

Salam Kitmitto

+971 50 276 9286

sakitmitto@mubadala.ae


For Partners Group

Prosek Partners

pro-partnersgroup@prosek.com

Stone Point Capital Closes Tenth Flagship Fund with $11.5 Billion of Committed Capital

 Fund Surpassed Hard Cap and Is the Largest Fundraise in the Firm’s History


(BUSINESS WIRE) -- Stone Point Capital LLC, a private equity firm focused on financial services and related industries, today announced the final closing of its tenth private equity fund, Trident X, with $11.5 billion in total commitments. Trident X exceeded its original target and hard cap of $9 billion and is approximately $2.5 billion larger than Trident IX, a $9 billion fund, which closed in 2022.


Trident X received strong support from its existing investor base, as well as first-time commitments from a number of leading institutional investors globally. General Partner and affiliated entities contributed approximately $750 million.


“We are grateful to our limited partners for their continued trust and support, and we are proud of the enduring strength of our Trident Funds over 30 years and many market cycles,” said Chuck Davis, Chairman and Co-Chief Executive Officer of Stone Point Capital. “With Trident X, we will continue doing what we believe we do best – proactively identifying exceptional owner-operators in and around the global financial services industry and helping them build lasting value in their businesses.”


Jim Carey, Co-Chief Executive Officer of Stone Point Capital, added, “We believe the consistency of our team, strategy and results continues to give us a distinct advantage in sourcing investments through our extensive network. We are excited by the opportunities we see for our tenth flagship fund and remain focused on creating value for our investors.”


Trident X began its investment period in May 2025 and has closed on one investment to date – Ultimus Fund Solutions, a provider of full-service fund administration services.


Stone Point has over 30 years of experience investing in the global financial services industry, beginning with private equity investments in insurance underwriting and expanding over time into a wide range of financial and business services sectors. Members of the senior leadership team have led operations since 1998. The Firm partners with experienced management teams and is flexible with respect to the types of transactions pursued through its Trident Funds. Stone Point has experience in standalone structured buyouts, as well as in carve-outs from larger organizations – bringing deep sector knowledge and an expansive network to every portfolio company engagement. Stone Point has invested in more than 160 companies across 10 active verticals and over 70 sub-sectors. The firm also has a credit-investing platform, Stone Point Credit, which has nearly $10 billion of assets under management.


Debevoise & Plimpton LLP acted as legal counsel for Stone Point in connection with the formation of Trident X.


About Stone Point Capital


Stone Point is an investment firm with more than $65 billion of assets under management across its private equity and credit platforms. Stone Point targets investments in companies in the global financial services industry and related sectors based primarily in North America and Western Europe. The firm invests in alternative asset classes, including private equity through its flagship Trident Funds and credit through commingled funds and separately managed accounts. In addition, Stone Point Capital Markets supports its firm, portfolio companies and other clients by providing dedicated financing solutions. For more information, please visit www.stonepoint.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250714531245/en/



Permalink

https://www.aetoswire.com/en/news/1407202547886


Contacts

Media Contacts

Prosek Partners

Caroline Gibson / Joshua Rosen

Pro-StonePoint@prosek.com


Stone Point Capital

Mary Manin

mmanin@stonepoint.com

Monday, July 14, 2025

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1


 OSAKA, Japan & CAMBRIDGE, Mass. - 

– Both Phase 3 Studies Met all Primary and Secondary Endpoints Demonstrating Statistically Significant Improvements Across Symptoms at All Doses, Building Upon Phase 2b Results


– Oveporexton was Generally Well-Tolerated in Phase 3 Safety Profile


– Takeda is Rapidly Advancing Regulatory Submissions and Launch Preparedness with the Aim to Bring Oveporexton to People Living with Narcolepsy Type 1 as Quickly as Possible


– These Results Mark a Major Advancement Toward Transforming the Standard of Care by Addressing the Underlying Cause of Narcolepsy Type 1


(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist, in narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin-producing neurons in the brain. Orexin agonists are designed to address this underlying orexin deficiency. For the first time, this mechanism of action has been validated in Phase 3 studies demonstrating significant improvement across a broad range of symptoms. These results reinforce the potential of oveporexton to transform the standard of care.


“We are thrilled to reach this pivotal milestone for the oveporexton program. Oveporexton is a testament to Takeda’s strength in discovering and developing a potential new class of medicines for difficult to treat diseases such as narcolepsy type 1,” said Christophe Weber, president and chief executive officer at Takeda. "Our leadership in orexin biology and building a multi-asset orexin franchise with transformative potential will position Takeda for long-term future growth.”


The FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) studies were two large, global Phase 3 studies conducted in 19 countries. Both studies achieved statistically significant improvement compared to placebo with p-values of <0.001 for all primary and secondary endpoints across all doses at week 12. The primary and secondary endpoints measuring objective and patient reported improvements in wakefulness, excessive daytime sleepiness, cataplexy, ability to maintain attention, overall quality of life and daily life functions demonstrate statistically significant and clinically meaningful improvements achieving near normal ranges across the broad range of symptoms investigated.


Oveporexton was generally well-tolerated with a safety profile from the Phase 3 studies overall consistent with oveporexton studies to date including the Phase 2b study. No serious treatment-related adverse events were reported. The most common adverse events were insomnia, urinary urgency and frequency. More than 95 percent of the participants who completed the studies enrolled in the ongoing long-term extension (LTE) study.


“We are grateful to the patients who took part in these clinical studies and to their families, the investigators and clinical staff. The studies were accelerated at an unprecedented pace with the aim to bring this potential treatment to people living with narcolepsy type 1 as quickly as possible,” said Andy Plump, M.D., Ph.D., president of R&D at Takeda. “The comprehensive assessments from our Phase 3 studies build on the transformative results we saw with our Phase 2b study with most participants reaching normative ranges and reporting clinically meaningful improvement across a broad range of symptoms at the end of the 12-week treatment period. The positive results also reinforce the continued momentum for our late-stage pipeline, which we believe will deliver value to the patients we serve around the world.”


Takeda intends to present the results at upcoming medical congresses and plans to submit a New Drug Application with the United States Food and Drug Administration and additional global regulatory authorities in fiscal year 2025.


Results from the Phase 3 studies have no significant impact on the full year consolidated forecast for the fiscal year ending March 31, 2026.


About Narcolepsy Type 1 (NT1) and Orexin Science


NT1 is a chronic, rare neurological disease that results in a range of debilitating symptoms including excessive daytime sleepiness (EDS), cataplexy, disrupted nighttime sleep, sleep paralysis and hallucinations upon falling asleep or waking. Additionally, individuals living with NT1 often report cognitive symptoms, including difficulty thinking clearly, remembering, concentrating and paying attention. NT1 is caused by loss of the orexin-producing neurons in the brain, which regulate wakefulness and sleep, and is also believed to be essential to other functions such as attention through activation of orexin receptors. Currently, the standard of care is limited to symptomatic therapies that may only partially address some of the symptoms people face.


About Oveporexton (TAK-861)


Oveporexton (TAK-861) is an investigational orexin receptor 2 (OX2R)-selective agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency that causes narcolepsy type 1 (NT1). By activating OX2Rs, oveporexton is designed to promote wakefulness and reduce abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy, to address the broad spectrum of daytime and nighttime symptoms.


About the FirstLight and RadiantLight Phase 3 Studies


FirstLight (TAK-861-3001; NCT06470828) and RadiantLight (TAK-861-3002; NCT06505031) are global, multicenter, placebo-controlled studies to evaluate the efficacy, safety and tolerability of oveporexton compared to placebo in patients with narcolepsy type 1 (NT1) over 12 weeks. The studies were conducted in 19 countries with enrollment completed within six months. The FirstLight study enrolled 168 participants randomized to one of three dosing arms (high dose, low dose and placebo). The RadiantLight study enrolled 105 participants randomized to two dosing arms (high dose and placebo). The primary endpoint in both studies was improvement in excessive daytime sleepiness (EDS) as measured by the Maintenance of Wakefulness Test (MWT), a standard measure of wakefulness. Key secondary endpoints included improvement in EDS as measured by the Epworth Sleepiness Scale (ESS) and in the Weekly Cataplexy Rate (WCR), a measure evaluating cataplexy. The studies also evaluated the effect of oveporexton on participants' ability to maintain attention, participants’ overall quality of life, the spectrum of narcolepsy symptoms and daily life functions, as well as the safety and tolerability of oveporexton.


About Takeda’s Orexin Agonists for Sleep-Wake Disorders


Takeda is leading the field of orexin science with a multi-asset franchise. Orexin is a key regulator of sleep and wake patterns and contributes to other essential functions including attention, mood, metabolism and respiration. Oveporexton (TAK-861) is the lead investigational orexin receptor 2 (OX2R) agonist asset in Takeda’s orexin franchise and received Breakthrough Therapy designation for the treatment of excessive daytime sleepiness in narcolepsy type 1 (NT1) from the U.S. Food and Drug Administration and the Center for Drug Evaluation of China’s National Medical Products Administration. The company is also investigating other orexin agonists in populations with orexin levels in the normal range, including TAK-360, an oral OX2R agonist initially being investigated for the treatment of narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and other potential indications where orexin signaling is implicated. ​


About Takeda


Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.


Important Notice


For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.


The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.


Forward-Looking Statements


This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.


Medical Information


This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250714054710/en/



Permalink

https://www.aetoswire.com/en/news/1407202547881


Contacts

Japanese Media

Yuko Yoneyama

yuko.yoneyama@takeda.com


U.S. and International Media

Rachel Wallace

rachel.wallace2@takeda.com